August 30, 2023

10x Ge­nomics has seen “in­cred­i­ble trac­tion” with its newest prod­uct, Xe­ni­um, ship­ping over 100 an­a­lyz­ers since launch­ing less than a year ago, CEO Serge Sax­onov

The FDA sent a warn­ing let­ter to Cal­i­for­nia-based eye drop man­u­fac­tur­er KC Phar­ma­ceu­ti­cals cit­ing sev­er­al is­sues re­lat­ed to the com­pa­ny’s qual­i­ty sys­tem. In the warn­ing

Bris­tol My­ers Squibb has scored an­oth­er win for its ane­mia drug Re­blozyl, re­veal­ing Mon­day evening the FDA grant­ed the drug its third in­di­ca­tion. The FDA

Pa­tients in Great Britain who take IV Tecen­triq now have a quick­er op­tion. The coun­try’s reg­u­la­to­ry au­thor­i­ty has ap­proved a sub­cu­ta­neous ver­sion of ate­zolizum­ab, bet­ter

Pfiz­er is chal­leng­ing the Covid-19 vac­cine patents that Mod­er­na has ac­cused the com­pa­ny of in­fring­ing be­fore the Patent Tri­al and Ap­peal Board (PT­AB), ar­gu­ing that

Sen. Raphael Warnock (D-GA) and eight oth­er Geor­gia law­mak­ers on Thurs­day asked the FDA for more trans­paren­cy over the short­age of can­cer drugs like cis­platin

The World Health Or­ga­ni­za­tion has se­cured li­cens­ing agree­ments with Medi­gen Vac­cine Bi­o­log­ics, the Uni­ver­si­ty of Chile and the Span­ish Na­tion­al Re­search Coun­cil (CSIC) to in­crease the

Ar­cutis is jump­ing in­to the pso­ri­a­sis TV ad mar­ket with its first-ever com­mer­cial for Zorvye, its non-steroid cream ap­proved in Ju­ly 2022. The mes­sage be­hind

Who’s on the list? That’s the ques­tion many in the phar­ma in­dus­try are ask­ing to­day about CMS re­leas­ing the names of the first 10 drugs,